title: Chronicles in drug discovery.
abstract: Chronicles in Drug Discovery is a series of brief reports on timely topics in the field of drug R&D. This month's chronicles contain the following reports: Targeting DNA repair enzymes instead of viral proteins provides a great advantage in preventing the emergence of resistant mutants. A striking increase in therapeutic approaches for the treatment of IBD has been fueled by an improved understanding of the mechanisms that underlie its pathophysiology. Peptide deformylase inhibitors are under active investigation for bacterial infections and cancer treatment. Dopamine D3 receptors present an attractive target for alcoholism therapy since they are involved in the mechanisms of alcohol dependency and abuse.
authors.affiliation: Prous Science, Barcelona, Spain. service@prous.com
authors.forename: V
authors.initials: V
authors.lastname: Khurdayan
authors.forename: J
authors.initials: J
authors.lastname: Bozzo
authors.forename: L
authors.initials: L
authors.lastname: Sorbera
mesh_terms: D000437:Alcoholism / Q000188:drug therapy; D000581:Amidohydrolases / Q000037:antagonists & inhibitors; D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology; D064007:Ataxia Telangiectasia Mutated Proteins; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors*; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors*; D018492:Dopamine Antagonists / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000503:physiopathology; D009025:Morpholines / Q000494:pharmacology; D009570:Nitriles / Q000494:pharmacology; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D011753:Pyrones / Q000494:pharmacology; D050637:Receptors, Dopamine D3 / Q000187:drug effects / Q000378:metabolism; D044005:Tetrahydroisoquinolines / Q000494:pharmacology; D025521:Tumor Suppressor Proteins / Q000037:antagonists & inhibitors*
chemical_list: C495818:2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one; D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D000998:Antiviral Agents; C481664:BB-83698; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D018492:Dopamine Antagonists; D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; D009025:Morpholines; D009570:Nitriles; D011753:Pyrones; D050637:Receptors, Dopamine D3; C409982:SB 277011; D044005:Tetrahydroisoquinolines; D025521:Tumor Suppressor Proteins; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; D017346:Protein Serine-Threonine Kinases; D000581:Amidohydrolases; C084507:peptide deformylase